Drug intelligence / Profile preview

AVA-ERL

Development stage: Preclinical
Lead developer: Avammune Therapeutics
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

AVA-ERL is a first-in-class tumor-targeted radioligand therapy (RLT) being developed by Avammune Therapeutics. It is designed to deliver a radioactive payload specifically to tumor cells by binding to a proprietary target. The drug is currently in the discovery stage for the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). As a radioligand therapy, it utilizes a targeting ligand to deliver a cytotoxic radioactive isotope directly to cancer cells, minimizing damage to healthy tissues.

Beyond the preview

Go deeper on AVA-ERL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVA-ERL.

Explore the full profile